A Phase I Study to Evaluate a Single Oral Dose of SRT2379 on the Endotoxin Induced Inflammatory Response in Healthy Male Subjects.
Phase of Trial: Phase I
Latest Information Update: 07 Aug 2017
At a glance
- Drugs SRT 2379 (Primary)
- Indications Diabetes mellitus
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 26 Jul 2011 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 20 Apr 2011 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
- 25 Mar 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.